Emcure Pharmaceuticals Limited (NSE:EMCURE)

India flag India · Delayed Price · Currency is INR
1,594.00
-58.70 (-3.55%)
Mar 30, 2026, 3:30 PM IST
Market Cap302.49B +62.9%
Revenue (ttm)88.50B +17.2%
Net Income8.70B +43.2%
EPS45.90 +39.7%
Shares Out189.59M
PE Ratio34.76
Forward PE27.50
Dividend3.00 (0.18%)
Ex-Dividend Daten/a
Volume275,305
Average Volume401,293
Open1,654.90
Previous Close1,652.70
Day's Range1,584.20 - 1,662.00
52-Week Range889.00 - 1,671.80
Betan/a
RSI59.12
Earnings DateMay 22, 2026

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the develop... [Read more]

Sector Healthcare
Founded 1981
Employees 6,731
Stock Exchange National Stock Exchange of India
Ticker Symbol EMCURE
Full Company Profile

Financial Performance

In fiscal year 2025, Emcure Pharmaceuticals's revenue was 78.96 billion, an increase of 18.59% compared to the previous year's 66.58 billion. Earnings were 6.81 billion, an increase of 36.76%.

Financial Statements